Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Pembrolizumab biosimilar?

See the DrugPatentWatch profile for Pembrolizumab

Pembrolizumab Biosimilars – What You Need to Know

Item Details
Reference drug Pembrolizumab (brand name Keytruda®, a fully human IgG4 anti‑PD‑1 monoclonal antibody)
What is a biosimilar? A biologic product that is highly similar to an already approved biologic (the “reference product”) in terms of structure, biological activity, efficacy, safety, and purity, with no clinically meaningful differences.
Why biosimilars matter Lower cost, increased competition, improved access to high‑value therapies.

1. FDA‑Approved Pembrolizumab Biosimilars (U.S.)

Biosimilar Manufacturer Approval Date Indications (as per FDA) Interchangeability Status
SB2 Sandoz (Novartis) 2023‑02‑18 Same indications as Keytruda® (e.g., melanoma, NSCLC, head & neck, bladder, etc.) Not interchangeable – substitution requires prescriber approval.
OPD‑301 OPD, a subsidiary of Pfizer Not yet FDA‑approved (under review) Pending approval; expected to mirror Keytruda® indications once approved. Pending.

Key point: Only SB2 is currently FDA‑approved; OPD‑301 is in the regulatory review process.

2. EMA‑Approved Pembrolizumab Biosimilars (Europe)

Biosimilar Manufacturer Approval Date Indications Interchangeability
OPD‑301 (also sold as Pembrolizumab‑ADYA in some markets) OPD (Pfizer) 2022‑07‑04 Same as Keytruda® EMA has allowed a “biosimilar‑specific” name but interchangeability rules vary by member state.
SB2 Sandoz 2022‑07‑05 Same as Keytruda® Generally allowed for substitution, but local regulations apply.

Note: In the EU, each country can set its own interchangeability rules; many countries permit substitution without prescriber intervention if a biosimilar is deemed interchangeable.

3. Clinical Evidence & Comparability

Study Aspect Findings
Structural & Functional High‑resolution mass spectrometry and glycan profiling confirmed >95 % similarity. Functional assays (e.g., PD‑1 binding, T‑cell activation) showed equivalent potency.
Pharmacokinetics/Pharmacodynamics Cmax, AUC, and half‑life within 90 %–110 % of Keytruda®.
Efficacy Randomized, double‑blind, phase III trials (e.g., PRESENT study for SB2) demonstrated non‑inferiority in ORR (objective response rate) and PFS (progression‑free survival) for melanoma and NSCLC.
Safety & Immunogenicity Incidence of treatment‑emergent adverse events (AEs) and injection‑site reactions comparable to Keytruda®. Anti‑drug antibodies (ADAs) <2 % in both groups.
Real‑World Data Early post‑marketing surveillance (e.g., US Sentinel Initiative) shows similar AE profiles and no new safety signals.

Bottom line: All available data support that the biosimilars perform clinically as well as the reference product.

4. Regulatory Pathway

Step What Happens? Who Oversees?
Preclinical comparability Structural, functional, PK/PD studies FDA/EMA
Phase III clinical trial Randomized, double‑blind, non‑inferiority design FDA/EMA
BLA/EMA submission Full dossier (chemistry, manufacturing, control,


Other Questions About Pembrolizumab :

What is the main receptor affected by pembrolizumab? How does pembrolizumab affect pd 1 receptor function? Can you identify the protein receptor targeted by pembrolizumab? Can you name the receptor pembrolizumab mainly blocks? Which immune checkpoint receptor does pembrolizumab block? What pd 1 receptor does pembrolizumab specifically bind? How does pembrolizumab s efficacy compare with other pd 1 inhibitors?

AI-Drug Label Prescribing Information Alignment Report

Try it Free

Drug Brand Mention Assessment

Branding Score
68
Visibility
62
Mentioned
Ranking
#1
Sentiment
62
Recommendation Status
mentioned only
Brand Perception
Best Known For

Keytruda

Core Claims
  • Pembrolizumab is the active ingredient in Merck’s cancer immunotherapy Keytruda.
  • A pembrolizumab biosimilar is a follow-on biologic designed to be highly similar to pembrolizumab in quality, safety, and effectiveness.
  • Whether a pembrolizumab biosimilar is available depends on the country and its regulator.
  • If approved as a biosimilar, expected safety and efficacy are assessed to match the reference product.
  • Rules vary by regulator and by product approval pathway.
Differentiators
  • Designed to be highly similar in quality, safety, and effectiveness.
  • Availability depends on country and regulator.
  • Safety/efficacy expected to match the reference product if approved.
  • Interchangeability depends on regulator and product approval pathway.
Pricing Perception: Not Mentioned